Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
To put it simply, if a GLP-1 or triple G-agonist even got rid of insulin requirement in 1 out of 10 new onset Type 1 diabetics, that would be a very big deal
I think that multi-target approach is really interesting, and Im excited about it because it could potentially lead to much greater weight loss and metabolic improvements than what weve seen with single-pathway drugs so far
Oral semaglutide (Rybelsus) formulations currently available include 3 mg, 7 mg and 14 mg tablets, with higher-dose tablets 25 mg and 50 mg are under investigation in OASIS trials for improved weight-loss efficacy[16]
India is home to over 100 million people with diabetes and approximately 250 million classified as obese or overweight.[15] What makes the situation uniquely dangerous is the Thin-Fat Indian paradox: South Asians tend to accumulate more visceral (belly) fat, liver fat, and less lean muscle mass at lower body weights than Western populations.[8][9][10] While GLP-1 medications are a global phenomenon, they are particularly critical for the Thin-Fat Indian phenotype
Kalia 2018) [Fig
